Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 11, Issue 12, Pages 3258
Publisher
MDPI AG
Online
2022-06-10
DOI
10.3390/jcm11123258
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomized, double‐blind, placebo‐ and positive‐controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects
- (2021) John O’Donnell et al. CTS-Clinical and Translational Science
- In vitro activity of sulbactam-durlobactam against extensive-drug-resistant Acinetobacter baumannii isolates belonging to South America major clones
- (2021) Carolina S. Nodari et al. Journal of Global Antimicrobial Resistance
- Genome sequencing and molecular characterisation of XDR Acinetobacter baumannii reveal complexities in resistance: Novel combination of sulbactam–durlobactam holds promise for therapeutic intervention
- (2021) Aniket Naha et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists
- (2021) Jacinda C. Abdul-Mutakabbir et al. Infectious Diseases and Therapy
- In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017
- (2020) Sarah M. McLeod et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety, Pharmacokinetics, and Drug:Drug Interaction Potential of Intravenous Durlobactam, a β-lactamase Inhibitor, in Healthy Subjects
- (2020) Jason D. Lickliter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China
- (2020) Qiwen Yang et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii
- (2020) Harald Seifert et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii
- (2020) Corneliu Ovidiu Vrancianu et al. Microorganisms
- Therapeutic options for difficult-to-treat Acinetobacter baumannii infections: a 2020 perspective
- (2020) Matteo Bassetti et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent
- (2019) Melissa D. Barnes et al. mBio
- β-Lactamases and β-Lactamase Inhibitors in the 21st Century
- (2019) Catherine L. Tooke et al. JOURNAL OF MOLECULAR BIOLOGY
- Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects
- (2019) John O'Donnell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections
- (2019) Maddalena Giannella et al. Open Forum Infectious Diseases
- Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
- (2019) Olexiy Sagan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam – epidemiology, laboratory detection and treatment implications
- (2018) Norelle Sherry et al. Expert Review of Anti-Infective Therapy
- Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects
- (2018) Keith A. Rodvold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities
- (2018) Muhammad Asif et al. Infection and Drug Resistance
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
- (2018) Simon Portsmouth et al. LANCET INFECTIOUS DISEASES
- Uncovering the mechanisms of Acinetobacter baumannii virulence
- (2017) Christian M. Harding et al. NATURE REVIEWS MICROBIOLOGY
- Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial
- (2017) Joseph Solomkin et al. JAMA Surgery
- Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant Porin
- (2017) Ramkumar Iyer et al. ACS Infectious Diseases
- Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514
- (2017) Adam B. Shapiro et al. ACS Infectious Diseases
- ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
- (2017) Thomas F. Durand-Réville et al. Nature Microbiology
- Combatting antimicrobial resistance globally
- (2016) Rebecca Sugden et al. Nature Microbiology
- Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
- (2014) J. Alexander Viehman et al. DRUGS
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More